A New Method to Quantify Population Variability for Toxicity Testing

On-Demand Webinar

Historically, toxicity testing has been conducted by giving lab animals high doses of chemicals and observing them for adverse events. But quantifying the risks chemicals pose to humans based on animal studies is problematic as the chemical doses are often orders of magnitude higher than environmental levels. Moreover, this process is slow, expensive, and ethically questionable. High-throughput in vitro screening (HTS) is gaining acceptance as an approach to toxicity testing that is efficient, economical, and humane. To fully leverage HTS to assess the risks chemicals pose to human health requires also considering the variability in responses to chemicals due to pharmacokinetic (PK) or pharmacodynamic (PD) differences among life-stages and subpopulations. In this webinar, Dr. Barbara Wetmore of the Hamner Institute  discussed how she led a team of Hamner, EPA, and Certara researchers to develop a new toxicity paradigm that estimates chemical-specific PK variability across multiple life-stages and subpopulations.

About Our Speaker

Barbara Wetmore, Senior Research Investigator, Hamner Institutes for Health Sciences. Dr. Wetmore is a Senior Research Investigator at The Hamner Institutes for Health Sciences. Her current research interests focus on the development and assessment of in vitro experimental and modeling tools that can be utilized to inform toxicity testing and risk assessment. She received her doctorate in Toxicology from North Carolina State University which was followed by a postdoctoral fellowship within the National Center for Toxicogenomics at the National Institute of Environmental Health Sciences. She has also served in various capacities as an expert or peer reviewer for organizations including the National Academy of Sciences, ECVAM, USEPA and Health Canada.

Historically, toxicity testing has been conducted by giving lab animals high doses of chemicals and observing them for adverse events. But quantifying the risks chemicals pose to humans based on animal studies is problematic as the chemical doses are often orders of magnitude higher than environmental levels. Moreover, this process is slow, expensive, and ethically questionable. High-throughput in vitro screening (HTS) is gaining acceptance as an approach to toxicity testing that is efficient, economical, and humane. To fully leverage HTS to assess the risks chemicals pose to human health requires also considering the variability in responses to chemicals due to pharmacokinetic (PK) or pharmacodynamic (PD) differences among life-stages and subpopulations. In this webinar, Dr. Barbara Wetmore of the Hamner Institute discussed how she led a team of Hamner, EPA, and Certara researchers to develop a new toxicity paradigm that estimates chemical-specific PK variability across multiple life-stages and subpopulations.